PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Merck & Co., Inc., Kenilworth, NJ 07033, USA.\', \'Pfizer Vaccine Research and Development, Pearl River, NY 10965, USA.\', \'Global Antibiotic Research & Development Partnership (GARDP), Geneva, Switzerland.\', \'Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St Louis, MO 63110, USA.\', \'National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.\', \'Foundation for the National Institutes of Health, 11400 Rockville Pike, Suite 600, North Bethesda, MD 20852, USA.\', \'Deloitte Consulting LLP, 200 Berkeley Street, Boston, MA 02116, USA.\', \'Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.\', \'Evotec ID Lyon, 40 Avenue Tony Garnier, 69007 Lyon, France. Electronic address: kara.carter@evotec.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1931-3128(20)30522-910.1016/j.chom.2020.09.017
?:doi
?:hasPublicationType
?:journal
  • Cell host & microbe
is ?:pmid of
?:pmid
?:pmid
  • 33152278
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33152278>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33152278>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all